Harrow (HROW) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free HROW Stock Alerts $12.07 +0.47 (+4.05%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 9:30 PM | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024May 13 at 4:34 PM | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Harrow Health (HROW)May 13 at 4:01 PM | businesswire.comHarrow Announces First Quarter 2024 Financial ResultsMay 13 at 7:00 AM | businesswire.comHarrow Names Greg DiPasquale as Senior Vice President, Head of CommercialMay 11 at 1:04 AM | americanbankingnews.comHarrow (HROW) Scheduled to Post Earnings on MondayMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)May 6, 2024 | marketbeat.comHarrow Health (HROW) Scheduled to Post Quarterly Earnings on MondayHarrow Health (NASDAQ:HROW) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589316)May 2, 2024 | seekingalpha.comHarrow: Merits A Buy On Sales PotentialMay 2, 2024 | seekingalpha.comHarrow: The Bull Thesis Is On Track, But Short-Term Challenges LoomApril 26, 2024 | insidertrades.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases $199,400.00 in StockApril 25, 2024 | marketbeat.comInsider Buying: Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Buys 20,000 Shares of StockHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. purchased 20,000 shares of the stock in a transaction on Thursday, April 25th. The stock was acquired at an average price of $9.97 per share, with a total value of $199,400.00. Following the acquisition, the insider now directly owns 3,815,000 shares in the company, valued at $38,035,550. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 25, 2024 | businesswire.comHarrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024April 25, 2024 | insidertrades.comOpaleye Management Inc. Purchases 11,715 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockApril 24, 2024 | marketbeat.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Opaleye Management Inc. Purchases 11,715 SharesHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. bought 11,715 shares of Harrow Health stock in a transaction dated Tuesday, April 23rd. The stock was acquired at an average cost of $10.29 per share, for a total transaction of $120,547.35. Following the completion of the transaction, the insider now directly owns 3,786,715 shares in the company, valued at $38,965,297.35. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.April 21, 2024 | insidertrades.comOpaleye Management Inc. Acquires 29,400 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockApril 20, 2024 | finance.yahoo.comHarrow, Inc. (HROW)April 19, 2024 | marketbeat.comInsider Buying: Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases 29,400 Shares of StockHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. bought 29,400 shares of Harrow Health stock in a transaction dated Friday, April 19th. The stock was purchased at an average price of $10.56 per share, with a total value of $310,464.00. Following the purchase, the insider now directly owns 3,775,000 shares in the company, valued at approximately $39,864,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 13, 2024 | marketbeat.comVanguard Group Inc. Has $25.29 Million Stock Holdings in Harrow Health, Inc. (NASDAQ:HROW)Vanguard Group Inc. raised its stake in Harrow Health, Inc. (NASDAQ:HROW - Free Report) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,759,879 shares of the company's stock after buying an additional 95,389 shares during the quaApril 11, 2024 | marketbeat.comHarrow Health (NASDAQ:HROW) Now Covered by Craig HallumCraig Hallum assumed coverage on Harrow Health in a research note on Thursday. They issued a "buy" rating and a $24.00 price objective for the company.April 3, 2024 | bizjournals.comMelt Pharmaceuticals raises $24 million for drug developmentApril 2, 2024 | finance.yahoo.comMelt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingMarch 29, 2024 | insidertrades.comOpaleye Management Inc. Acquires 50,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 28, 2024 | marketbeat.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Purchases $641,000.00 in StockHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. purchased 50,000 shares of the business's stock in a transaction dated Thursday, March 28th. The shares were acquired at an average cost of $12.82 per share, for a total transaction of $641,000.00. Following the acquisition, the insider now owns 3,745,600 shares of the company's stock, valued at approximately $48,018,592. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.March 26, 2024 | insidertrades.comMark L. Baum Acquires 9,000 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 25, 2024 | marketbeat.comInsider Buying: Harrow Health, Inc. (NASDAQ:HROW) CEO Acquires 9,000 Shares of StockHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) CEO Mark L. Baum purchased 9,000 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The stock was acquired at an average price of $11.59 per share, for a total transaction of $104,310.00. Following the purchase, the chief executive officer now owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 25, 2024 | marketbeat.comB. Riley Cuts Harrow Health (NASDAQ:HROW) Price Target to $26.00B. Riley reduced their price target on Harrow Health from $30.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday.March 23, 2024 | insidertrades.comOpaleye Management Inc. Acquires 50,600 Shares of Harrow Health, Inc. (NASDAQ:HROW) StockMarch 22, 2024 | marketbeat.comHarrow Health, Inc. (NASDAQ:HROW) Major Shareholder Opaleye Management Inc. Buys 50,600 SharesHarrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. acquired 50,600 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were bought at an average price of $9.65 per share, with a total value of $488,290.00. Following the completion of the transaction, the insider now directly owns 3,695,600 shares of the company's stock, valued at $35,662,540. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 21, 2024 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comWhy Is Harrow (HROW) Stock Up 5% Today?March 20, 2024 | msn.comHarrow Health Non-GAAP EPS of -$0.20 misses by $0.15, revenue of $36.36M misses by $1.5MMarch 19, 2024 | investorplace.comHROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023March 19, 2024 | finance.yahoo.comHarrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023March 19, 2024 | businesswire.comHarrow Announces Fourth Quarter and Year-End 2023 Financial ResultsMarch 18, 2024 | marketbeat.comShort Interest in Harrow Health, Inc. (NASDAQ:HROW) Expands By 9.1%Harrow Health, Inc. (NASDAQ:HROW - Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 29th, there was short interest totalling 5,490,000 shares, an increase of 9.1% from the February 14th total of 5,030,000 shares. Based on an average trading volume of 379,100 shares, the short-interest ratio is currently 14.5 days.March 18, 2024 | benzinga.comEarnings Preview: Harrow HealthMarch 13, 2024 | finance.yahoo.comHarrow (HROW) Fell on Lowering the GuidanceMarch 10, 2024 | marketbeat.comKennedy Capital Management LLC Acquires Shares of 121,808 Harrow Health, Inc. (NASDAQ:HROW)Kennedy Capital Management LLC acquired a new stake in Harrow Health, Inc. (NASDAQ:HROW - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 121,808 shares of the company's stock, valued at approximately $1,750,000. Kennedy CapitaMarch 5, 2024 | finance.yahoo.comHarrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024March 4, 2024 | marketbeat.comStifel Financial Corp Buys New Position in Harrow Health, Inc. (NASDAQ:HROW)Stifel Financial Corp bought a new stake in shares of Harrow Health, Inc. (NASDAQ:HROW - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 340,092 shares of the company's stock, valued at approximately $4,887,000. Stifel Financial Corp owned 0.97March 1, 2024 | marketbeat.comHarrow Health, Inc. (NASDAQ:HROW) Shares Acquired by Braidwell LPBraidwell LP raised its position in shares of Harrow Health, Inc. (NASDAQ:HROW - Free Report) by 24.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,808,684 shares of the company's stock after purchasing an additional 3February 29, 2024 | finance.yahoo.comHere’s How Harrow (HROW) Weighed on SRK Capital’s PerformanceFebruary 15, 2024 | businesswire.comHarrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical ProductsFebruary 6, 2024 | marketbeat.comJump Financial LLC Invests $1.04 Million in Harrow Health, Inc. (NASDAQ:HROW)Jump Financial LLC acquired a new position in shares of Harrow Health, Inc. (NASDAQ:HROW - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 72,223 shares of the company's stoJanuary 21, 2024 | marketbeat.comRice Hall James & Associates LLC Purchases Shares of 250,380 Harrow Health, Inc. (NASDAQ:HROW)Rice Hall James & Associates LLC acquired a new position in shares of Harrow Health, Inc. (NASDAQ:HROW - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 250,380 shares of the company's stJanuary 11, 2024 | msn.comHarrow says dry eye drug Vevye now available in USJanuary 11, 2024 | finance.yahoo.comHarrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye DiseaseJanuary 3, 2024 | bizjournals.comHarrow Inc. partners with technology companies for dry eye prescription VevyeDecember 15, 2023 | marketbeat.comShort Interest in Harrow Health, Inc. (NASDAQ:HROW) Drops By 20.0%Harrow Health, Inc. (NASDAQ:HROW - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 4,890,000 shares, a drop of 20.0% from the November 15th total of 6,110,000 shares. Based on an average daily trading volume, of 682,900 shares, the short-interest ratio is presently 7.2 days.December 9, 2023 | markets.businessinsider.comHarrow Health’s Strong Sales Growth and Strategic Acquisitions Fuel Buy Rating Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address America’s worst nightmare? (Ad)What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late. Click here to watch this bombshell exposé now. HROW Media Mentions By Week HROW Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HROW News Sentiment▼0.480.57▲Average Medical News Sentiment HROW News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HROW Articles This Week▼92▲HROW Articles Average Week Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Erasca News Mereo BioPharma Group News Rani Therapeutics News ADC Therapeutics News Amarin News Terns Pharmaceuticals News Alto Neuroscience News Nature's Sunshine Products News Corbus Pharmaceuticals News Mersana Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HROW) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry ResearchNot Trump. Not Biden. But ___________.The Freeport SocietyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
